Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

The literature on colorectal cancer is certainly still unclear ... the FLEX trial before committing to the widespread use of cetuximab in patients with NSCLC.boxed-text Addition of cetuximab ...

Pfizer has shared positive results from a late-stage study of its Braftovi (encorafenib) combination in BRAF V600E-mutant ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

Cetuximab has clearly increased the therapeutic armamentarium for the treatment of patients with mCRC. Studies looking at clinical, biochemical, and molecular markers for increased activity have ...

The currently approved administration schedule for cetuximab is the weekly schedule (400 mg/m 2 initial dose followed by 250 mg/m 2 weekly); however, the commonly used chemotherapy agents for CRC ...